StocksMedium•8 October 2026•
1 min read
argenx FB102 Celiac Disease Study Meets Primary Endpoint in Phase 2 Trial
Key Facts
1The Phase 2 study of FB102 met its primary endpoint, showing it can prevent gluten-induced intestinal damage in celiac disease patients.
2argenx plans to advance FB102 into Phase 3 development following the successful Phase 2 readout.
The Phase 2 study of FB102 met its primary endpoint, showing it can prevent gluten-induced intestinal damage in celiac disease patients. GlobeNewswire reported that argenx plans to advance the drug into Phase 3 development following the successful trial readout.
These results represent the first clinical readout for FB102 since argenx acquired Forte Biosciences in August 2026. Regarding market performance, ARGX closed at $928.44 on October 7, 2026, after reaching a session high of $942.69.